ARCHIVES

As ImClone Investigation Continues, FDA Combines Drugs, Biologics Review; Memo Describes “Lengthy Process” That Led To FDA Decision; Oncology Community Praises FDA Move

This article is from The Cancer Letter archive.

Vol. 28 No. 33 | September 13, 2002

Download PDF Visit The Full Archive

Related Articles

Control-Arm CML Patients In Phase III Gleevec Study Allowed To Switch.

January 25, 2002

CCIRC Okays New Effort To Rate Disease Committees, Modalities In Groups, Effective with Next Round

November 20, 1981

In Brief: Cancer Program A “Noble Venture,” Kennedy Says; $937 Million Not Enough, Upton Says

April 13, 1979

In Brief: House Appropriations Committee Gives NCI $725 Million, Smallest Increase Since 1970

June 1, 1975

NCI Plans a Catalog Of Research Tools

April 30, 1999

Columbia Univ. Places cDNA Libraries In Public Domain

April 28, 1995